Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Astellas Pharma ADR (ALPMY)

Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bernstein Reaffirms Their Hold Rating on Astellas Pharma (ALPMF) Tipranks - Sat Oct 11, 2025

In a report released today, Miki Sogi from Bernstein maintained a Hold rating on Astellas Pharma, with a price target of Yen1,600.00. The company’s shares closed last Friday at $11.10.Elevate Your Investing...

ALPMY : 14.0700 (+1.96%)
ALPMF : 12.8500 (-6.69%)
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 PR Newswire - Wed Oct 1, 2025

- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -

ALPMY : 14.0700 (+1.96%)
Astellas Announces Top Management Personnel Change PR Newswire - Mon Sep 29, 2025

TOKYO , Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced the following changes to its Top Management...

ALPMY : 14.0700 (+1.96%)
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program" PR Newswire - Wed Jul 16, 2025

- Supporting Korean Startups' Drug Discovery Research and Global Expansion -

ALPMY : 14.0700 (+1.96%)
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst Motley Fool - Tue Oct 29, 2024

It has been a rotten year for Apellis Pharmaceuticals stock, but better times could be ahead.

BAC : 63.49 (+0.94%)
ALPMY : 14.0700 (+1.96%)
APLS : 41.03 (-0.07%)
Here Are the 3 George Soros Stocks Most Likely to Turn $200,000 Into $1 Million Over the Next 20 Years Motley Fool - Sun Sep 24, 2023

The multibillionaire's portfolio features some moneymaking ideas.

MSFT : 489.24 (-0.72%)
GOOG : 362.46 (-3.43%)
GOOGL : 364.68 (-3.43%)
ALPMY : 14.0700 (+1.96%)
AMZN : 271.72 (-2.05%)
Why Shares of Annexon Are Plummeting Thursday Motley Fool - Thu May 25, 2023

Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.

ALPMY : 14.0700 (+1.96%)
ISEE : 39.95 (+0.38%)
APLS : 41.03 (-0.07%)
ANNX : 5.38 (+0.94%)
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today Motley Fool - Mon May 1, 2023

These three biotech stocks were on the volatile side today.

TGTX : 49.36 (+1.27%)
VKTX : 33.29 (+1.06%)
ALPMY : 14.0700 (+1.96%)
APLS : 41.03 (-0.07%)
ISEE : 39.95 (+0.38%)
FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021, in New York. Pfizer will spend about $43 billion to buy Seagen and broaden its reach into cancer treatments, the pharmaceutical giant said Monday, March 13, 2023. (AP Photo/Mark Lennihan, File)
Pfizer buys Seagen for $43B, boosts access to cancer drugs Associated Press - Mon Mar 13, 2023

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue

ALPMY : 14.0700 (+1.96%)
$SPX : 7,742.59 (+0.08%)
$DOWI : 54,580.64 (+0.91%)
$IUXX : 29,644.67 (-0.30%)
PFE : 25.52 (+0.43%)

Barchart Exclusives

LITE Stock Alert: Analysts See Big Upside Ahead for Lumentum as Trump Aims to Restrict Chinese Data Center Components Barchart - 7 minutes ago
Lumentum shares are already up about 130% in 2026, while strong earnings growth and a $1,100 analyst target suggest Wall Street sees further upside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.